Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.
Latest From Pricing Debate
Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.
HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.
Viren Mehta, founder of Mehta Partners, LLC, considers the oft-repeated statement that the cost of drugs represents only 10% of US healthcare expenditure. Does it matter that the figure excludes a large and growing segment of medicine spending?
Budget proposal to fund state Medicaid programs through per capita cap or block grant would save $610bn over 10 years, administration says; budget calls for clarifying treatment of value-based pricing and fostering exchange of pre-approval information between manufacturers and payers.
Amid an escalating tussle with the health ministry over the level of South Korean drug prices, foreign pharma firms operating in the country are now proposing the launch of a new joint study on the issue with the incoming government.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.
Former Obama Administration official offers sophisticated and complicated approach to value-based pricing, tied back to drug development costs. The complexity alone makes the idea a non-starter for the current Administration, but it also begs the question of whether it would be more likely to cut costs – or just increase R&D spending?
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.